Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Restenosis Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Restenosis Overview | 7 | 1 |
| Pipeline Products for Restenosis Comparative Analysis | 8 | 1 |
| Restenosis Therapeutics under Development by Companies | 9 | 1 |
| Restenosis Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Restenosis Pipeline Products Glance | 11 | 2 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Restenosis Products under Development by Companies | 13 | 1 |
| Restenosis Products under Investigation by Universities/Institutes | 14 | 1 |
| Restenosis Companies Involved in Therapeutics Development | 15 | 3 |
| Bio3 Research S.r.l | 15 | 1 |
| CytoTools AG | 16 | 1 |
| XBiotech Inc | 17 | 1 |
| Restenosis Therapeutics Assessment | 18 | 10 |
| Assessment by Monotherapy Products | 18 | 1 |
| Assessment by Combination Products | 19 | 1 |
| Assessment by Target | 20 | 2 |
| Assessment by Mechanism of Action | 22 | 2 |
| Assessment by Route of Administration | 24 | 2 |
| Assessment by Molecule Type | 26 | 2 |
| Drug Profiles | 28 | 13 |
| (connective tissue growth factor + insulin human) Drug Profile | 28 | 1 |
| alendronate sodium Drug Profile | 29 | 1 |
| Antibodies to Antagonize HMGB-1 for Cardiovascular Diseases Drug Profile | 30 | 2 |
| CV-18C3 Drug Profile | 32 | 2 |
| didox Drug Profile | 34 | 3 |
| HMW-02Ak Drug Profile | 37 | 1 |
| HMW-02Ap Drug Profile | 38 | 1 |
| HO-3867 Drug Profile | 39 | 1 |
| TW-01 Drug Profile | 40 | 1 |
| Restenosis Dormant Projects | 41 | 2 |
| Restenosis Discontinued Products | 43 | 1 |
| Restenosis Product Development Milestones | 44 | 3 |
| Featured News &Press Releases | 44 | 1 |
| Jan 03, 2013: XBiotech Receives Fast Track Designation From FDA For True Human Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a For Restenosis | 44 | 1 |
| Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease | 44 | 1 |
| Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites | 45 | 1 |
| Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease | 46 | 1 |
| Appendix | 47 | 2 |
| Methodology | 47 | 1 |
| Coverage | 47 | 1 |
| Secondary Research | 47 | 1 |
| Primary Research | 47 | 1 |
| Expert Panel Validation | 47 | 1 |
| Contact Us | 47 | 1 |
| Disclaimer | 48 | 1 |